source
- Cue Biopharma's chronic hives drug clears Phase 2 trial, first immunology data after cancer pivotCue Biopharma announced that its candidate for chronic spontaneous urticaria successfully completed a Phase 2 trial in China. The trial marks the company's first clinical data since it shifted its…
- Beacon eye gene therapy hits mark in late-stage studyBeacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.